August 24, 2014 / 4:26 PM / in 3 years

Roche to buy U.S. biotech firm InterMune for $8.3 bln

LONDON, Aug 24 (Reuters) - Roche Holding AG has agreed to buy U.S. biotech company InterMune Inc for $8.3 billion in cash, marking the latest multibillion-dollar deal in a consolidating pharmaceutical sector, Roche said on Sunday.

The Swiss drugmaker will pay $74.00 a share for InterMune, representing a premium of 38 percent to the closing price on Aug. 22. (Reporting by Ben Hirschler, Editing by Angus MacSwan)

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below